Market Research Logo

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016’, provides an overview of the Metastatic Hepatocellular Carcinoma (HCC) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Metastatic Hepatocellular Carcinoma (HCC)
    • The report reviews pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC) by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Metastatic Hepatocellular Carcinoma (HCC) therapeutics and enlists all their major and minor projects
    • The report assesses Metastatic Hepatocellular Carcinoma (HCC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC)
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC)
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Metastatic Hepatocellular Carcinoma (HCC) Overview
    Therapeutics Development
    Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Overview
    Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis
    Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Development by Companies
    Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Investigation by Universities/Institutes
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Products Glance
    Clinical Stage Products
    Early Stage Products
    Metastatic Hepatocellular Carcinoma (HCC) - Products under Development by Companies
    Metastatic Hepatocellular Carcinoma (HCC) - Products under Investigation by Universities/Institutes
    Metastatic Hepatocellular Carcinoma (HCC) - Companies Involved in Therapeutics Development
    Acceleron Pharma, Inc.
    AstraZeneca Plc
    AVEO Pharmaceuticals, Inc.
    Celgene Corporation
    Eisai Co., Ltd.
    Eli Lilly and Company
    F. Hoffmann-La Roche Ltd.
    HanAll Biopharma Co., Ltd.
    Johnson & Johnson
    Millennium Pharmaceuticals Inc
    Mirna Therapeutics, Inc.
    Molecular Partners AG
    MolMed S.p.A.
    Novartis AG
    OncoMed Pharmaceuticals, Inc.
    Pfizer Inc.
    PharmAbcine, Inc.
    Verlyx Pharma Inc.
    Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    AV-203 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AZD-9150 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CC-122 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy for Metastatic Hepatocellular Carcinoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    codrituzumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    crizotinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dalantercept - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    emibetuzumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    erdafitinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    golvatinib tartrate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HL-143 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ipafricept - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LY-3039478 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LY-3127804 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MP-0250 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MRX-34 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NGR-hTNF - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OSU-2S - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    palbociclib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pasireotide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pentamidine isethionate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PF-04518600 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PTX-9908 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sapanisertib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sonidegib phosphate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    temsirolimus - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TTAC-0001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    utomilumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects
    Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products
    Metastatic Hepatocellular Carcinoma (HCC) - Product Development Milestones
    Featured News & Press Releases
    Jul 30, 2013: Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio
    May 13, 2013: Marina Biotech's Licensee Mirna Therapeutics Initiates Phase I Clinical Trial Of Anticancer Drug MRX34
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H2 2016
    Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Acceleron Pharma, Inc., H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AstraZeneca Plc, H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Celgene Corporation, H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Eisai Co., Ltd., H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Eli Lilly and Company, H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Johnson & Johnson, H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Mirna Therapeutics, Inc., H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Molecular Partners AG, H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by MolMed S.p.A., H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Novartis AG, H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Pfizer Inc., H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by PharmAbcine, Inc., H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Verlyx Pharma Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects, H2 2016
    Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H2 2016
    Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report